Summary
Bristol-Myers Squibb is a global pharmaceutical company facing both transition risks (patent expiries) and opportunities (new oncology/immunology therapies). While its 4% dividend and pipeline progress appeal to value investors, high leverage and 2024 losses require cautious monitoring. The stock suits income-focused investors comfortable with turnaround execution risk.
Bull Case
BMY’s discounted valuation (8.5x forward P/E) prices in worst-case scenarios. Successful launches of Sotyktu and subcutaneous Opdivo could drive $5B+ incremental revenue by 2026. The 4% dividend remains covered by pharma’s recession-resistant cash flows, while debt reduction accelerates post-2025 patent cliffs.
Bear Case
Mounting losses (-$8.95B net income 2024) and $39B debt may force dividend cut despite 4% yield. Pipeline delays (only 2/10 Phase 3 drugs approved) and Medicare price cuts could make current P/S ratio of 2.5x look expensive. Opdivo’s 2028 patent expiry looms without clear successor.
Recent News
- Positive Phase 3 trial results for Sotyktu (psoriasis) and EU approvals for Breyanzi (non-Hodgkin lymphoma) & Opdivo (liver cancer) may drive growth (Source).
- Jim Cramer highlights BMY as more attractive than Merck due to valuation and pipeline potential (Source).
- Trading at 4.13% dividend yield with Motley Fool citing as a discounted dividend stock (Source).
Financial Analysis
- Revenue grew 7.3% YoY to $48.3B in 2024 (vs $45B in 2023), but Q4 2024 saw -94% YoY net income decline to $72M.
- Debt burden worsened: Net Debt/EBITDA spiked to 12.4x in 2024 (vs 1.46x in 2023) due to $39.3B net debt and declining EBITDA.
- R&D investment increased to $11.16B in 2024 (+20% YoY), signaling pipeline focus.
- Dividend sustainability concern: Negative EPS (-4.41) and -185% net profit margin (2024) conflict with 4.13% yield.
- Value signals: P/S of 2.53x and Forward P/E of 8.54x below industry averages suggest undervaluation.
- Liquidity risk: Quick ratio fell to 0.81 in 2024 (vs 0.91 in 2023), with interest coverage at -3.3x.
While BMY shows revenue growth and pipeline momentum, deteriorating profitability (2024 net loss of $8.95B) and leveraged balance sheet (Debt/Equity 3.13x) create execution risk. Low beta (0.436) suggests defensive characteristics, but dividend coverage relies on successful commercialization of new therapies like Sotyktu.
Screener Ratings
Compare over 5500 companies with our screener ratings at AIpha.io.
Overall: 6
Balanced risk/reward: Attractive yield and pipeline upside vs leveraged balance sheet and execution risks
Value: 7
Undervalued vs peers (P/S 2.53x vs industry 4.5x) with catalysts from new drug launches
Growth: 5
Near-term headwinds from patent cliffs offset by medium-term pipeline optionality
Dividend: 6
High yield but coverage concerns: FCF ($13.9B) covers dividend ($7.5B), but net losses persist
Defensive: 8
Low beta (0.436) and essential medicines provide recession resilience
Moat: 6
Durable oncology/immunology franchises but lacks unassailable IP position
S.W.O.T. Analysis
Strengths:
- Top 10 global pharma with $48B revenue base
- 6 recent regulatory approvals (EU Opdivo SC, Breyanzi etc.)
- 4%+ dividend yield supported by $1.39B FCF (2024)
Weaknesses:
- $39.3B net debt burden (3.13x Debt/Equity)
- 2024 ROIC of -7.7% shows capital inefficiency
- Patent expiries (Eliquis 2026, Opdivo 2028)
Opportunities:
- Subcutaneous Opdivo approval (EU decision by June 2025)
- Sotyktu adoption in $25B psoriasis market
- Cost rationalization ($1.5B savings target)
Threats:
- IRA drug price negotiations impacting 65% of US portfolio
- Generic competition for Revlimid (already declined 75% YTD)
- R&D pipeline failures in crowded oncology space
Industry Overview
Threat of New Competitors: High barriers (FDA approvals, R&D costs) protect incumbents
Competition Among Existing Firms: Intense (vs Merck, Pfizer) with patent cliffs driving innovation race
Suppliers’ Bargaining Power: Moderate (specialized API suppliers) mitigated by scale
Buyers’ Bargaining Power: High (PBMs/government payors pressure drug pricing)
Threat of Substitute Products: Moderate-High (biosimilars/generics post-patent expiry)
Competitive Advantage
Cost Advantage: Limited – 75.1% gross margin (Q3 2024) shows pricing power but high SG&A/R&D costs
Intangible Assets: Strong – $14.56B book value (2023) understates IP value of Opdivo/Eliquis franchises
Network Effect: Weak – Pharma lacks network effects
Switching Costs: Moderate – Physician familiarity with therapies creates retention
Warning: This document has been generated by an advanced customised AI prompted with financial data derived from company filings and other reputable sources. The process is specifically designed to minimise hallucinations, however the output is not 100% reliable. It is essential to check any information in this document before relying on it for financial decisions. You can find the underlying data used here.
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.